Reconstitution and Dosing Recommendations for GLOW Peptide
GLOW peptide (growth hormone releasing peptide) should be reconstituted with bacteriostatic water and administered at a dose of 100-200 μg per day, typically via subcutaneous injection.
Reconstitution Protocol
Materials Needed
- Lyophilized GLOW peptide
- Bacteriostatic water for injection
- Sterile syringe (1ml insulin syringe recommended)
- Alcohol swabs
Reconstitution Steps
- Clean the rubber stopper of both vials with alcohol swabs
- Draw the appropriate amount of bacteriostatic water into the syringe
- Slowly inject the bacteriostatic water into the GLOW peptide vial, directing the stream against the glass wall to avoid foaming
- Gently swirl the vial until completely dissolved (do not shake)
- Store reconstituted peptide in refrigerator (2-8°C)
Dosing Recommendations
Standard Dosing
- Initial dose: 100 μg per day
- Maintenance dose: 100-200 μg per day
- Administration frequency: Once daily, preferably at the same time each day
Administration Route
- Subcutaneous injection is the preferred route
- Intranasal administration has also shown efficacy at doses of 5-20 μg/kg 1
Treatment Duration
- Clinical studies have demonstrated efficacy with treatment durations of 3-6 months 1
- Some studies have extended treatment to 18-24 months with continued efficacy 1
Clinical Considerations
Monitoring Parameters
- Height velocity in pediatric patients
- Serum IGF-1 levels
- GH binding protein concentrations
Expected Outcomes
- Increased height velocity in children with short stature (from baseline 3.7 cm/year to approximately 6.0 cm/year) 1
- Increased GH binding protein concentrations
Potential Side Effects
- Mild facial flushing (typically 1-3 minutes duration)
- Potential increases in insulin and glucose levels 2
- Generally well-tolerated with no significant changes in cortisol, prolactin, or thyroid hormone levels 2
Special Populations
Pediatric Patients
- Dosing in children has been studied at 5-15 μg/kg twice daily for 3 months, then three times daily 1
- Demonstrated significant increases in height velocity in children with short stature
Adults with GH Deficiency
- Oral GHRP-mimetic compounds (such as MK-677) have shown efficacy at doses of 10-50 mg daily 2
- Response may be greater in those with less severe GH/IGF-I deficiency at baseline
Important Precautions
- Somatostatin analogues should be discontinued prior to GHRP administration as they may interfere with receptor targeting 3
- For long-acting somatostatin analogues: discontinue 4-6 weeks before GHRP treatment
- For short-acting somatostatin analogues: discontinue at least 24 hours before GHRP treatment
The efficacy of GLOW peptide appears to be dose-dependent, with higher doses producing greater stimulation of GH secretion 4, 5. Unlike traditional GH therapy, GHRP works by stimulating the body's own GH secretion through specific receptors present at both pituitary and hypothalamic levels 6.